Grants for Nonprofits - Federal

This funding opportunity provides financial support to various organizations, including governments and nonprofits, to help the Government of Kenya enhance and maintain digital health systems for effective disease monitoring and public health management.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites U01 cooperative agreement applications for Physical Sciences-Oncology Network (PS-ON). The goal of the PS-ON is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The research projects funded through this FOA, individually and as a collaborative Network along with other funded research projects, will support transdisciplinary research that: (1) drives a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

This funding opportunity provides financial support to nonprofit organizations and educational institutions to establish American Innovation Hubs in Indonesia, focusing on AI-driven learning and digital skills development for youth and creative professionals.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to support the archiving and documentation of existing data sets within the scientific mission of the NICHD in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in July 2024 with an expected application due date in October 2024. This NOFO will utilize the R03 activity code. Details of the planned NOFO are provided below.

This funding opportunity supports nonprofit organizations and educational institutions in Argentina to create a business acceleration program for small and medium-sized enterprises in industrial and mining sectors, enhancing their operational efficiency and innovation.

This funding opportunity provides financial support to organizations working to promote fair labor practices and responsible investment in critical industries, enhancing workforce development and competitiveness in the U.S.

This funding opportunity provides financial support to nonprofit organizations and other eligible entities to develop innovative projects that strengthen trade and investment ties between the United States and Africa, promoting economic growth and collaboration.

The purpose of this Notice of Funding Opportunity (NOFO) is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Pseudomonas aeruginosa. A number of Gram-negative bacterial pathogens are associated with the alarming increase in rates of drug resistance in healthcare and community settings. This group includes carbapenem-resistant Acinetobacter , carbapenem-resistant Enterobacterales (CRE), and MDR Pseudomonas aeruginosa that have been designated as “urgent” or “serious” threats in a recent report by the Centers for Disease Control and Prevention (CDC). A significant threat arises from the lack of effective therapeutic options available to treat some of these infections and is exacerbated by the scarcity of novel compounds effective against antimicrobial resistant (AR) and multidrug-resistant (MDR) Gram-negative bacteria in the discovery and development pipeline. In recent years, several public forums (including NIAID-sponsored workshops) identified the lack of understanding of the principles that govern compound penetration into, and efflux out of, Gram-negative bacteria as a key bottleneck for the rational discovery of novel lead therapeutic compounds. The paucity of suitable assays/tools/models to inform structure-activity relationships and guide optimization of whole cell penetration (and efflux avoidance) is reflected in the failure of medicinal chemistry efforts to advance novel chemical classes of compounds with Gram-negative activity. As more Gram-negative bacteria become resistant to antimicrobials and therapeutic options become limited or nonexistent, it becomes imperative to understand and rationalize the principles that allow molecules to penetrate Gram-negative bacteria, while avoiding efflux and overt toxicity toward eukaryotic cells. Therefore, developing new assays, tools, and models is paramount for overcoming this key bottleneck and facilitating the development of novel compounds targeting Gram-negative pathogens. Research Objectives and Scope The objective of this NOFO is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms aimed at gaining a better understanding of the rules and compound properties that govern the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens. This NOFO also supports the preclinical development of novel Gram-negative antibacterial therapeutics based on the tools and models hereby developed. Applications must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and/or MDR Pseudomonas aeruginosa. Projects should complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria. This NOFO will also support subsequent preclinical development of a promising lead antibacterial. Given the complex challenges of this research, this initiative encourages applications from multi-disciplinary teams composed of relevant experts in areas such as bacterial physiology, microbiology, bacterial membrane biology, medicinal chemistry, pharmacology, computation, and specialized technologies (microscopy, spectroscopy, electrophysiology, machine learning, etc.), as appropriate. Collaboration with, and utilization of, the NIAID Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB), is recommended for completion of project relevant medicinal chemistry tasks. Close collaboration between academic and industry partners is highly encouraged to optimally combine innovative basic science with drug discovery expertise and proper access to compound libraries more typically available from industry. Examples of assay and model development activities include, but are not limited to: Quantitative cellular (or model system) assays to measure drug penetration and efflux, independent from standard minimum inhibitory concentration (MIC) testing; Innovative quantitative assays to measure drug concentrations in the bacterial cytoplasm and/or periplasmic space; Innovative technologies for dissecting and assessment of the kinetics of drug penetration and efflux from bacteria; and Computational algorithms for describing/predicting physical-chemical properties/guidelines needed by small molecules for optimal Gram-negative penetration and efflux avoidance. Applicants should demonstrate the utility of the developed tools and/or assays to predict and measure potency of candidate therapeutics against Gram-negative targets through one or more approaches. For example, using the developed models and/or assays to guide a medicinal chemistry campaign aimed at producing a novel chemical series with Gram-negative activity; screening existing libraries using the computational algorithms developed as a tool to find compounds with Gram-negative activity; or profiling existing libraries of compounds with known Gram-negative activity. Applications including the following will be considered non-responsive and will not be reviewed: Projects that do not focus on at least one select Gram-negative pathogen (carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, or MDR Pseudomonas aeruginosa); Projects focused only on Gram-positive bacteria or Mycobacterium tuberculosis; Projects that do not focus on penetration and efflux of small molecules; Applications not containing a Milestone and Timeline attachment; Applications proposing Clinical trials; and Research on HIV/AIDS.

This funding opportunity supports researchers in developing innovative animal models and biological tools to advance the understanding of Down syndrome and its related health conditions.

This funding opportunity provides financial support to various organizations for projects that promote the use of wood products and energy, enhance forest health, and stimulate economic growth in forested communities across the U.S.

This funding opportunity supports large-scale, collaborative research projects focused on aging, inviting diverse institutions and organizations to integrate their efforts around a common scientific question.

This funding opportunity supports innovative research projects that explore how climate change affects cancer risks, treatment, and survivorship, with a focus on developing solutions to mitigate these impacts and address health inequities.

The U.S. Embassy to Papua New Guinea of the U.S. Department of State announces an open competition to submit a statement of interested to implement the Civil Society Partnership Program: Building Organizational Capacity program focusing on empowering non-profits and civil society organizations in Papua New Guinea. This Program will emphasize holistic interventions that address fundamental inequalities and empower vulnerable groups, paving the way for a more peaceful and prosperous nation. By investing in the leadership development and public engagement capacity of these organizations, this program aims to drive positive social change and create a more equitable and thriving future for all Papua New Guineans.

This funding opportunity provides financial support for non-profit organizations and educational institutions to implement public diplomacy projects that promote economic recovery and strengthen partnerships between the United States and Venezuela.

The "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that further develop and validate innovative technologies for analyzing molecular and cellular aspects of cancer, with the goal of improving cancer research, detection, diagnosis, treatment, and understanding of health disparities.

This grant provides funding for researchers to investigate the biological mechanisms behind adverse effects related to anti-beta-amyloid immunotherapy in Alzheimer's disease, with the goal of developing strategies to protect the blood-brain barrier and improve treatment safety.

This funding opportunity is designed for eligible institutions to expand and modernize facilities that breed Specific Pathogen Free non-human primates, essential for advancing HIV/AIDS research.

This funding opportunity supports U.S.-based organizations in developing and testing effective cancer interventions that improve health outcomes for diverse populations across the entire cancer control continuum, particularly in under-resourced communities.

The Administration for Children and Families, Administration on Children, Youth and Families' Family and Youth Services Bureau announces the anticipated availability of funds under the General Departmental Sexual Risk Avoidance Education (GDSRAE) Program. The purpose of the GDSRAE Program is to fund projects to implement sexual risk avoidance education that teach participants how to voluntarily refrain from non-marital sexual activity. The services are targeted to participants that reside in areas with high rates of teen births and/or are at greatest risk of contracting sexually transmitted infections (STIs). The goals of GDSRAE are to empower participants to make healthy decisions, and provide tools and resources to prevent pregnancy, STIs, and youth engagement in other risky behaviors. Successful applicants are expected to submit program plans that agree to: use medically accurate information referenced to peer-reviewed publications by 1) educational, scientific, governmental, or health organizations; 2) implement sexual risk avoidance curricula and/or strategies with an evidence-based approach integrating research findings with practical implementation that aligns with the needs and desired outcomes for the intended audience; and 3) teach the benefits associated with self-regulation, success sequencing for poverty prevention, healthy relationships, goal setting, and resisting sexual coercion, dating violence, and other youth risk behaviors such as underage drinking or illicit drug use without normalizing teen sexual activity.

This funding opportunity provides support for organizations involved in a nationwide study that examines how early life exposures, particularly prenatal substance use, affect children's brain development and health outcomes.